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Introduction 43
Carbapenem-resistant Pseudomonas aeruginosa bloodstream infection 44 (CRPA-BSI) has been associated with high morbidity and mortality in 45 hematopoietic stem cell transplantation (HSCT) patients. Nowadays, it is a 46 challenge with limited therapeutic options (1-2). Thus, in vitro synergy studies 47 are important to define combination therapy that can be useful to treat these 48 infections. To date, few studies evaluated antimicrobial synergy against CRPA 49 (3 5) and the role of virulence on the high mortality associated with CRPA-BSI 50 is controversial as well (2, 3) . 51 Therefore, we aimed to describe the clinical data of 30 patients with CRPA-52 BSI from January 2012 to December 2014, at the Hospital das Clínicas of 53 University of Sao Paulo, Brazil. In vitro synergy, pulsed field gel 54 electrophoresis (PFGE) and PCR for carbapenemases (SPM; KPC, VIM, 55 NDM) and virulence genes (lasAprotease lasBelastase; exoSexoenzyme S; 56 toxAexotoxin A; phzMphenazine-specific methyltransferase) of the 30 strains, 57
including those identified during the outbreak that occurred in our hospital in (6) and Pitt bacteraemia score was calculated (7). All patients 75 received levofloxacin as prophylaxis during neutropenia. Initial antibiotic 76 therapy was considered appropriate when colistin (COL) was administered 77 within 24 hours after obtain blood culture. All patients received 2g of 78 meropenem (MERO) tid, prolonged infusions (3 hours) adjusted for kidney 79 function when indicated. Amikacin (AMK) was added to therapy with colistin 80 and meropenem whenever CRPA was susceptible. 81
Minimum inhibitory concentrations (MIC) of COL (USP Reference Standard, 82
Página4 microdilution method according to the Clinical and Laboratory Standards 85 Institute (8). Time-kill assay was performed in duplicate with drugs alone and 86 combined at 1x MIC and 0.5x MIC as previously reported (9-10). Aliquots 87 were removed at time 0 and 2, 4, 6, and 24 hours and serially diluted in 0.85% 88 sodium chloride solution. Diluted samples of 0.01 mL were plated on Müeller-89
Hinton agar, and the colonies were counted (log 10 cfu/mL) after 20 hours of 90 incubation at 37°C. Synergy was interpreted as a ≥ 2 log 10 decrease in colony 91 count with the combination compared to the most active single agent; was 92 considered antagonistic for a ≥ 2 log 10 increase in cfu/mL, and indifferent for a 93 < 2 log 10 increase or decrease in count (9-10). Bivariate Cox regressions were 94 used to evaluated 14-day mortality using SPSS software version 21 (SPSS 95
Inc., USA), value of p less than 5% was considered significant. 96
The strains presented MERO MIC90 > 512µg/mL; two thirds were also 97 resistant to AMK (MIC 2-512 µg/mL) and all were susceptible to COL ( Table  98 1). The combination of COL plus MERO achieved synergy in 57% of isolates, 99 COL plus AMK in 2/30 isolates (6.6%), and of MERO plus AMK in 33% 100 (10/30), only in isolates susceptible to AMK (table 2) . Although, highly 101 resistant to meropenem, half of the isolates achieved in vitro synergy with 102 combination of meropenem with colistin, and the group that received this 103 combination showed a tendency towards lower mortality (6 of 7 patients that 104 survived received meropenem plus colistin) (p=0.06). Zusman et al (2013) 105 performed a meta-analysis and found similar results for in vitro combination of 106 carbapenem and polymixin B or colistin in 59% of 43 CRPA isolates (4). 107
Página5 vs. 17% p = 0,012). Patients treated with two or three drugs did not present a 110 statistically significant difference in 14-day death (29 % x44% p = 0,65) (table  111 2). 112
Five clones named as A, B, C, D and E harboured SPM and belonged to 113 ST277 were found by PFGE during the study period (table 1) . ST277 is 114 common in Brazil and has been described in several outbreaks including 115 patients who travelled to the country (13-16). Interestingly, the six strains that 116 co-harbored KPC were distributed in four clones, except the predominant 117 clone named as clone A. We did not find exoU in our strains, on the other 118 hand, patients with CRPA BSI caused by strains harboring gene lasB evolved 119 more frequent to death (88.9% vs. 57.1%). This virulence factor is associated 120 with bacterial enzyme production of elastase that degrades immunoglobulin 121 and complement factor (12). In Brazil, the gene exoU was described in CRPA 122 belonging to ST2237 in burn patients instead of ST277 (17). 123
The most frequent carbapenemase identified was bla SPM , and six isolates co-124 harboured bla KPC as shown in table 1.The five clones sequenced by illumina 125 were assigned as ST277 and harbored the Tn4371 (Table 3 ). In all the strains, 126 mutations on outer membrane protein OprD (T103S, K115T, V118P, F170L) 127
OprM (A261T), OprJ (D68G, M69V) were found, as well as the mexT gene 128 that possessed a mutation resulting in a frameshift. The 16S rRNA 129 methyltransferase gene rmtD1, which confers high-level resistance to all 130 aminoglycosides and has been associated to ST277 was present only in 131 clones I, IV and V. Clone III did not harbor fosA, it carried exoS and toxA of 132 
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Iib; gene aac(6')-Streptomycin 3''-adenylyltransferase. Gene. aadA7.
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Fluoroquinolone resistance gene: aac(6')Ib-cr.
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Phenicol resistance gene: chloramphenicol export protein gene, chloramphenicol acetyltransferase (catB7) and CMX.
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Metallo-beta-lactamase: SPM 
